



Press release November 1, 2016

Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that production of a proprietary GABA drug has started. Concurrently, the Scientific and Medical Advisory Board is expanded with two leading experts in rheumatoid arthritis and type 2 diabetes, Professor Daniel Furst, University of California, Los Angeles (UCLA) and Associate Professor Michael Alvarsson, Clinic Director at the Karolinska University Hospital.

Diamyd Medical has as previously reported broadened its operations to include type 2 diabetes and rheumatoid arthritis with its own GABA drug. Development of a GABA-drug product has now been launched in collaboration with a supplier of GMP production and preclinical studies to determine the dose and formulation start shortly.

To further strengthen its expertise in type 2 diabetes and rheumatoid arthritis, Diamyd Medical has expanded its Scientific and Medical Advisory Board with two new members, Professor Daniel Furst and Associate Professor Michael Alvarsson.

Daniel Furst, Professor at the University of California, Los Angeles (UCLA) and rheumatologist, has published over 800 articles and 15 books, including 430 scientific publications, in his field. Doctor Furst's research include clinical pharmacology of anti-rheumatic drugs and the pathophysiology and treatment of systemic sclerosis.

Michael Alvarsson is Senior Consultant Physician at the Department of Endocrinology, Metabolism and Diabetes at Karolinska University Hospital and Associate Professor at the Karolinska Institute, where he conducts clinical diabetes research at the Department of Molecular Medicine and Surgery. Doctor Alvarsson has long experience from clinical studies in type 2 diabetes as principal investigator for numerous multinational clinical trials.

About Diamyd Medical

Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd[®], an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd[®]. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB (former Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company's Certified Adviser.

For further information, please contact:

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: www.diamyd.com

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on November 1, 2016.